相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas Defines Molecular Subtypes and Identifies Therapeutic Targets
Renata Ferrarotto et al.
CLINICAL CANCER RESEARCH (2021)
Immuno-radiotherapy with cetuximab and avelumab for advanced stage head and neck squamous cell carcinoma: Results from a phase-I trial
Joris B. W. Elbers et al.
RADIOTHERAPY AND ONCOLOGY (2020)
PI3K/AKT/mTOR signaling as a molecular target in head and neck cancer
Franziska E. Marquard et al.
BIOCHEMICAL PHARMACOLOGY (2020)
Novel EGFR ectodomain mutations associated with ligand-independent activation and cetuximab resistance in head and neck cancer
Sindhu Nair et al.
PLOS ONE (2020)
Long noncoding RNA FOXD2-AS1 enhances chemotherapeutic resistance of laryngeal squamous cell carcinoma via STAT3 activation
Rui Li et al.
CELL DEATH & DISEASE (2020)
TGF-Beta-Activated Cancer-Associated Fibroblasts Limit Cetuximab Efficacy in Preclinical Models of Head and Neck Cancer
Ksenia M. Yegodayev et al.
CANCERS (2020)
Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open -label phase III study
R. L. Ferris et al.
ANNALS OF ONCOLOGY (2020)
Integrated single-cell and bulk gene expression and ATAC-seq reveals heterogeneity and early changes in pathways associated with resistance to cetuximab in HNSCC-sensitive cell lines
Luciane T. Kagohara et al.
BRITISH JOURNAL OF CANCER (2020)
AXL Mediates Cetuximab and Radiation Resistance Through Tyrosine 821 and the c-ABL Kinase Pathway in Head and Neck Cancer
Nellie K. McDaniel et al.
CLINICAL CANCER RESEARCH (2020)
Multi-Institutional Randomized Double-Blind Phase II Trial of Everolimus vs. Placebo as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)
C.A.O. Nathan et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2020)
An open-label, non-randomized, multi-arm, phase II trial evaluating pembrolizumab combined with cetuximab in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): updated results of cohort 1 analysis
A.G. Sacco et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2020)
Preliminary activity of tipifarnib in tumors of the head and neck, salivary gland and urothelial tract with HRAS mutations.
Alan Loh Ho et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Pathway-Specific Genome Editing of PI3K/mTOR Tumor Suppressor Genes Reveals that PTEN Loss Contributes to Cetuximab Resistance in Head and Neck Cancer
Hiroki Izumi et al.
MOLECULAR CANCER THERAPEUTICS (2020)
CD44s Induces miR-629-3p Expression in Association with Cisplatin Resistance in Head and Neck Cancer Cells
Junichiro Chikuda et al.
CANCERS (2020)
The Immune Subtypes and Landscape of Squamous Cell Carcinoma
Bailiang Li et al.
CLINICAL CANCER RESEARCH (2019)
Immunogenomic correlates of response to cetuximab monotherapy in head and neck squamous cell carcinoma
Daniel L. Faden et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2019)
MET activation confers resistance to cetuximab, and prevents HER2 and HER3 upregulation in head and neck cancer
Ofra Novoplansky et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
miR-96-5p targets PTEN expression affecting radio-chemosensitivity of HNSCC cells
Mahrou Vahabi et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
EACH: A randomised phase II study evaluating the safety and anti-tumour activity of the combination of avelumab and cetuximab relative to avelumab monotherapy in recurrent/metastatic head and neck squamous cell cancer.
Martin David Forster et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Preclinical efficacy of copanlisib in cetuximab sensitive and resistant tumors of HNSCC.
Konrad Friedrich Klinghammer et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
PTEN loss is associated with resistance to cetuximab in patients with head and neck squamous cell carcinoma
Nnamdi Eze et al.
ORAL ONCOLOGY (2019)
Cetuximab-Containing Combinations in Locally Advanced and Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Miren Taberna et al.
FRONTIERS IN ONCOLOGY (2019)
Molecular and Clinical Activity of CDX-3379, an Anti-ErbB3 Monoclonal Antibody, in Head and Neck Squamous Cell Carcinoma Patients
Umamaheswar Duvvuri et al.
CLINICAL CANCER RESEARCH (2019)
AKR1C1 controls cisplatin-resistance in head and neck squamous cell carcinoma through cross-talk with the STAT1/3 signaling pathway
Wei-Min Chang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial
Douglas Adkins et al.
LANCET ONCOLOGY (2019)
Clinical update on head and neck cancer: molecular biology and ongoing challenges
Elham Alsahafi et al.
CELL DEATH & DISEASE (2019)
Multi-kinase inhibitors and cisplatin for head and neck cancer treatment in vitro
Roman C. Brands et al.
ONCOLOGY LETTERS (2019)
Preferential Response of Basal-Like Head and Neck Squamous Cell Carcinoma Cell Lines to EGFR-Targeted Therapy Depending on EREG-Driven Oncogenic Addiction
Sylvie Job et al.
CANCERS (2019)
Heterogeneity of the Head and Neck Squamous Cell Carcinoma Immune Landscape and Its Impact on Immunotherapy
Madison Canning et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2019)
Pleiotropic Effects of Epithelial Mesenchymal Crosstalk on Head and Neck Cancer: EMT and beyond
T. B. Steinbichler et al.
CANCER MICROENVIRONMENT (2019)
Differential escape mechanisms in cetuximab-resistant head and neck cancer cells
Christopher D. Willey et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2019)
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
Georgina Long et al.
LANCET ONCOLOGY (2019)
Neuregulin Signaling Is a Mechanism of Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma
Marta Baro et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Aberrant HER3 ligand heregulin-expressing head and neck squamous cell carcinoma is resistant to anti-EGFR antibody cetuximab, but not second-generation EGFR-TKI
Kimio Yonesaka et al.
ONCOGENESIS (2019)
1118PDAvelumab-cetuximab-radiotherapy versus standards of care (SoC) in patients (pts) with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Safety phase of randomized trial GORTEC 2017-01 (REACH)
Y Tao et al.
ANNALS OF ONCOLOGY (2019)
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
Barbara Burtness et al.
LANCET (2019)
Targeting the EGFR and Immune Pathways in Squamous Cell Carcinoma of the Head and Neck (SCCHN): Forging a New Alliance
Nabil F. Saba et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Resveratrol Targets Urokinase-Type Plasminogen Activator Receptor Expression to Overcome Cetuximab-Resistance in Oral Squamous Cell Carcinoma
Katsuhiro Uzawa et al.
SCIENTIFIC REPORTS (2019)
Nicotine promotes lymph node metastasis and cetuximab resistance in head and neck squamous cell carcinoma
Rieko Shimizu et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2019)
Patritumab or placebo, with cetuximab plus platinum therapy in recurrent or metastatic squamous cell carcinoma of the head and neck: A randomised phase II study
Martin D. Forster et al.
EUROPEAN JOURNAL OF CANCER (2019)
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
Ezra E. W. Cohen et al.
LANCET (2019)
Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC The Phase 2 CONDOR Randomized Clinical Trial
Lillian L. Siu et al.
JAMA ONCOLOGY (2019)
Effective treatment of squamous cell carcinoma of the head and neck (HNSCC) using a combined regimen of tipifarnib and cetuximab
Lihua Shu et al.
CANCER RESEARCH (2019)
Rational combination with PDK1 inhibition overcomes cetuximab resistance in head and neck squamous cell carcinoma
Haiquan Lu et al.
JCI INSIGHT (2019)
Exosomal miR-196a derived from cancer-associated fibroblasts confers cisplatin resistance in head and neck cancer through targeting CDKN1B and ING5
Xing Qin et al.
GENOME BIOLOGY (2019)
Adaptive Responses to Monotherapy in Head and Neck Cancer: Interventions for Rationale-Based Therapeutic Combinations
Sankar Jagadeeshan et al.
TRENDS IN CANCER (2019)
AXL mediates cetuximab resistance through tyrosine 821 and activation of c-Abl kinase in head and neck cancer
Nellie K. McDaniel et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Immune Evasion by Head and Neck Cancer: Foundations for Combination Therapy
Joshua D. Horton et al.
TRENDS IN CANCER (2019)
Clinical Development of Molecular Targeted Therapy in Head and Neck Squamous Cell Carcinoma
Paul Gougis et al.
JNCI CANCER SPECTRUM (2019)
Cancer immunogenomic approach to neoantigen discovery in a checkpoint blockade responsive murine model of oral cavity squamous cell carcinoma
Paul Zolkind et al.
ONCOTARGET (2018)
Anti-EGFR antibody cetuximab is secreted by oral squamous cell carcinoma and alters EGF-driven mesenchymal transition
Toshifumi Fujiwara et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2018)
miR-204 inhibits angiogenesis and promotes sensitivity to cetuximab in head and neck squamous cell carcinoma cells by blocking JAK2-STAT3 signaling
Qingwei Wu et al.
BIOMEDICINE & PHARMACOTHERAPY (2018)
BET Inhibition Overcomes Receptor Tyrosine Kinase-Mediated Cetuximab Resistance in HNSCC
Brandon Leonard et al.
CANCER RESEARCH (2018)
A Phase I Clinical Trial of AZD1775 in Combination with Neoadjuvant Weekly Docetaxel and Cisplatin before Definitive Therapy in Head and Neck Squamous Cell Carcinoma
Eduardo Mendez et al.
CLINICAL CANCER RESEARCH (2018)
MicroRNA-139-5p affects cisplatin sensitivity in human nasopharyngeal carcinoma cells by regulating the epithelial-to-mesenchymal transition
Qianqian Shao et al.
GENE (2018)
Overexpression of PIK3CA in head and neck squamous cell carcinoma is associated with poor outcome and activation of the YAP pathway
Ramon Garcia-Escudero et al.
ORAL ONCOLOGY (2018)
Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma
Renata Ferrarotto et al.
ORAL ONCOLOGY (2018)
Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
Robert L. Ferris et al.
ORAL ONCOLOGY (2018)
FGFR signaling regulates resistance of head and neck cancer stem cells to cisplatin
Sarah C. McDermott et al.
Oncotarget (2018)
Integrated time course omics analysis distinguishes immediate therapeutic response from acquired resistance
Genevieve Stein-O'Brien et al.
GENOME MEDICINE (2018)
Combining Immunotherapy and Radiotherapy for Cancer Treatment Current Challenges and Future Directions
Yifan Wang et al.
FRONTIERS IN PHARMACOLOGY (2018)
Alteration of the Antitumor immune Response by Cancer-Associated Fibroblasts
Linda Ziani et al.
FRONTIERS IN IMMUNOLOGY (2018)
Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck The Active8 Randomized Clinical Trial
Robert L. Ferris et al.
JAMA ONCOLOGY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
A phase I/II trial adding poly(ADP-ribose) polymerase (PARP) inhibitor veliparib to induction carboplatin-paclitaxel (Carbo-Tax) in patients with head and neck squamous cell carcinoma (HNSCC) Alliance A091101.
Michael J. Jelinek et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Mechanism of acquired resistance to cetuximab in head and neck cancer.
Arun Khattri et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
PAK2-c-Myc-PKM2 axis plays an essential role in head and neck oncogenesis via regulating Warburg effect
Amit Gupta et al.
CELL DEATH & DISEASE (2018)
1049PDResults of a phase II study evaluating monalizumab in combination with cetuximab in previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
J Fayette et al.
ANNALS OF ONCOLOGY (2018)
Molecular Markers of Anticancer Drug Resistance in Head and Neck Squamous Cell Carcinoma: A Literature Review
Sandra Lopez-Verdin et al.
CANCERS (2018)
The molecular landscape of head and neck cancer
C. Rene Leemans et al.
NATURE REVIEWS CANCER (2018)
Predictive biomarkers for combined chemotherapy with 5-fluorouracil and cisplatin in oro- and hypopharyngeal cancers
Yasuhisa Hasegawa et al.
MOLECULAR AND CLINICAL ONCOLOGY (2018)
Anti PD-L1 DUrvalumab combined with Cetuximab and RadiOtherapy in locally advanced squamous cell carcinoma of the head and neck: A phase I/II study (DUCRO)
Pierluigi Bonomo et al.
CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY (2018)
Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals
Gulidanna Shayan et al.
CLINICAL CANCER RESEARCH (2018)
Cetuximab Resistance in Head and Neck Cancer Is Mediated by EGFR-K521 Polymorphism
Friederike Braig et al.
CANCER RESEARCH (2017)
HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models
Dongsheng Wang et al.
CLINICAL CANCER RESEARCH (2017)
CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer
Raghvendra M. Srivastava et al.
CLINICAL CANCER RESEARCH (2017)
Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN
Laura Q. M. Chow et al.
CLINICAL CANCER RESEARCH (2017)
Combination of phosphotidylinositol-3-kinase targeting with cetuximab and irradiation: A preclinical study on an orthotopic xenograft model of head and neck cancer
Alexandre Bozec et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2017)
Cancer stem cell mediated acquired chemoresistance in head and neck cancer can be abrogated by aldehyde dehydrogenase 1 A1 inhibition
Safeena Kulsum et al.
MOLECULAR CARCINOGENESIS (2017)
Identification of evolutionarily conserved DNA damage response genes that alter sensitivity to cisplatin
Anna V. Gaponova et al.
ONCOTARGET (2017)
T-cell immunoglobulin mucin 3 blockade drives an antitumor immune response in head and neck cancer
Jian-Feng Liu et al.
MOLECULAR ONCOLOGY (2017)
An immunogenic personal neoantigen vaccine for patients with melanoma
Patrick A. Ott et al.
NATURE (2017)
Tumor Mutational Burden and Response Rate to PD-1 Inhibition
Mark Yarchoan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
IL6 is associated with response to dasatinib and cetuximab: Phase II clinical trial with mechanistic correlatives in cetuximab-resistant head and neck cancer
L. P. Stabile et al.
ORAL ONCOLOGY (2017)
The role of toll-like receptor 4 in tumor microenvironment
Jing Li et al.
ONCOTARGET (2017)
Increased PD-1+ and TIM-3+ TILs during Cetuximab Therapy Inversely Correlate with Response in Head and Neck Cancer Patients
Hyun-Bae Jie et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Reversing EGFR Mediated Immunoescape by Targeted Monoclonal Antibody Therapy
Fernando Concha-Benavente et al.
FRONTIERS IN PHARMACOLOGY (2017)
Cross Talk between inhibitory immunoreceptor Tyrosine-Based Activation Motif-Signaling and Toll-Like Receptor Pathways in Macrophages and Dendritic Cells
Ivan Hirsch et al.
FRONTIERS IN IMMUNOLOGY (2017)
Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways
Ping Wee et al.
CANCERS (2017)
Midkine derived from cancer-associated fibroblasts promotes cisplatin-resistance via up-regulation of the expression of lncRNA ANRIL in tumour cells
Dongya Zhang et al.
SCIENTIFIC REPORTS (2017)
Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Head and Neck Cancer
Sidharth V. Puram et al.
CELL (2017)
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab
Nadeem Riaz et al.
CELL (2017)
SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells
Hiroyuki Ozawa et al.
CLINICAL CANCER RESEARCH (2017)
A 13-gene expression-based radioresistance score highlights the heterogeneity in the response to radiation therapy across HPV-negative HNSCC molecular subtypes
Jean-Philippe Foy et al.
BMC MEDICINE (2017)
Lymphotoxin-β Interacts with Methylated EGFR to Mediate Acquired Resistance to Cetuximab in Head and Neck Cancer
Dennis Shin-Shian Hsu et al.
CLINICAL CANCER RESEARCH (2017)
Suppression of Lymphocyte Functions by Plasma Exosomes Correlates with Disease Activity in Patients with Head and Neck Cancer
Sonja Ludwig et al.
CLINICAL CANCER RESEARCH (2017)
SDF-1/CXCR4 expression in head and neck cancer and outcome after postoperative radiochemotherapy
Chiara De-Colle et al.
CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY (2017)
Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies B2M Inactivation Impairing Immunorecognition
Carolina Pereira et al.
CLINICAL CANCER RESEARCH (2017)
NEDD4 is involved in acquisition of epithelial-mesenchymal transition in cisplatin-resistant nasopharyngeal carcinoma cells
Shaoyan Feng et al.
CELL CYCLE (2017)
Elevated basal antibody-dependent cell-mediated cytotoxicity (ADCC) and high epidermal growth factor receptor (EGFR) expression predict favourable outcome in patients with locally advanced head and neck cancer treated with cetuximab and radiotherapy
Laura Lattanzio et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
Current events in immunotherapy for upper aerodigestive tract cancer
Sophie Outh-Gauer et al.
ANNALES DE PATHOLOGIE (2017)
Chemotherapy for recurrent/metastatic head and neck cancers
Andy Karabajakian et al.
ANTI-CANCER DRUGS (2017)
Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFNγ That Induce PD-L1 Expression in Head and Neck Cancer
Fernando Concha-Benavente et al.
CANCER RESEARCH (2016)
Activin Receptor-like Kinase 1 Ligand Trap Reduces Microvascular Density and Improves Chemotherapy Efficiency to Various Solid Tumors
Lukas J. A. C. Hawinkels et al.
CLINICAL CANCER RESEARCH (2016)
Phase II trial of bevacizumab plus cetuximab plus cisplatin with concurrent intensity-modulated radiation therapy for patients with stage III/IVB head and neck squamous cell carcinoma
Matthew G. Fury et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2016)
Epidermal growth factor is a potential biomarker for poor cetuximab response in tongue cancer cells
Anna Ansell et al.
JOURNAL OF ORAL PATHOLOGY & MEDICINE (2016)
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy
Weiyi Peng et al.
CANCER DISCOVERY (2016)
Tumor-associated fibroblast-conditioned medium induces CDDP resistance in HNSCC cells
Teresa Bernadette Steinbichler et al.
ONCOTARGET (2016)
Safety of the natural killer (NK) cell-targeted anti-KIR antibody, lirilumab (liri), in combination with nivolumab (nivo) or ipilimumab (ipi) in two phase 1 studies in advanced refractory solid tumors
N. H. Segal et al.
ANNALS OF ONCOLOGY (2016)
Phase I trial of cetuximab, intensity modulated radiotherapy (IMRT), and ipilimumab in previously untreated, locally advanced head and neck squamous cell carcinoma (PULA HNSCC)
J. Bauman et al.
ANNALS OF ONCOLOGY (2016)
Phase II randomized trial of radiation therapy, cetuximab, and pemetrexed with or without bevacizumab in patients with locally advanced head and neck canceraEuro
A. Argiris et al.
ANNALS OF ONCOLOGY (2016)
Exercise-Induced Dose-Response Alterations in Adiponectin and Leptin Levels Are Dependent on Body Fat Changes in Women at Risk for Breast Cancer
Kathleen Sturgeon et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2016)
Mutational Landscape and Sensitivity to Immune Checkpoint Blockers
Roman M. Chabanon et al.
CLINICAL CANCER RESEARCH (2016)
Functional Genomics Uncover the Biology behind the Responsiveness of Head and Neck Squamous Cell Cancer Patients to Cetuximab
Paolo Bossi et al.
CLINICAL CANCER RESEARCH (2016)
Up-regulation of Histone Methyltransferase, DOT1L, by Matrix Hyaluronan Promotes MicroRNA-10 Expression Leading to Tumor Cell Invasion and Chemoresistance in Cancer Stem Cells from Head and Neck Squamous Cell Carcinoma
Lilly Y. W. Bourguignon et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
TP53 Mutations in Head and Neck Squamous Cell Carcinoma and Their Impact on Disease Progression and Treatment Response
Ge Zhou et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2016)
Cetuximab Resistance in Squamous Carcinomas of the Upper Aerodigestive Tract Is Driven by Receptor Tyrosine Kinase Plasticity: Potential for mAb Mixtures
Ida Kjaer et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab
Mari Iida et al.
MOLECULAR CANCER THERAPEUTICS (2016)
A Phase I Trial to Evaluate Antibody-Dependent Cellular Cytotoxicity of Cetuximab and Lenalidomide in Advanced Colorectal and Head and Neck Cancer
Erin M. Bertino et al.
MOLECULAR CANCER THERAPEUTICS (2016)
PI3Kγ is a molecular switch that controls immune suppression
Megan M. Kaneda et al.
NATURE (2016)
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
R. L. Ferris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
OX40 signaling in head and neck squamous cell carcinoma: Overcoming immunosuppression in the tumor microenvironment
R. Bryan Bell et al.
ORAL ONCOLOGY (2016)
The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations
Jessica L. Geiger et al.
ORAL ONCOLOGY (2016)
Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer
Ruth J. Davis et al.
ORAL ONCOLOGY (2016)
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
Itay Tirosh et al.
SCIENCE (2016)
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
Shohei Koyama et al.
NATURE COMMUNICATIONS (2016)
Liquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinoma
Friederike Braig et al.
ONCOTARGET (2016)
CTLA4 blockade reduces immature myeloid cells in head and neck squamous cell carcinoma
Guang-Tao Yu et al.
ONCOIMMUNOLOGY (2016)
LAG-3 confers poor prognosis and its blockade reshapes antitumor response in head and neck squamous cell carcinoma
Wei-Wei Deng et al.
ONCOIMMUNOLOGY (2016)
MicroRNA profiling of cisplatin-resistant oral squamous cell carcinoma cell lines enriched with cancer-stem-cell-like and epithelial-mesenchymal transition-type features
Ruma Dey Ghosh et al.
SCIENTIFIC REPORTS (2016)
NK cells and cancer: you can teach innate cells new tricks
Maelig G. Morvan et al.
NATURE REVIEWS CANCER (2016)
The head and neck cancer immune landscape and its immunotherapeutic implications
Rajarsi Mandal et al.
JCI INSIGHT (2016)
A Phase 1 Study of Cetuximab and Lapatinib in Patients With Advanced Solid Tumor Malignancies
John F. Deeken et al.
CANCER (2015)
Decreased SMAD4 expression is associated with induction of epithelial-to-mesenchymal transition and cetuximab resistance in head and neck squamous cell carcinoma
Haixia Cheng et al.
CANCER BIOLOGY & THERAPY (2015)
AXL Mediates Resistance to PI3Kα Inhibition by Activating the EGFR/PKC/mTOR Axis in Head and Neck and Esophageal Squamous Cell Carcinomas
Moshe Elkabets et al.
CANCER CELL (2015)
Immunosuppressive activity of cancer-associated fibroblasts in head and neck squamous cell carcinoma
Hideyuki Takahashi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
CTLA-4+ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis
Hyun-Bae Jie et al.
CANCER RESEARCH (2015)
Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
Michael S. Rooney et al.
CELL (2015)
Molecular Pathways: Sensitivity and Resistance to Anti-EGFR Antibodies
Andrea Bertotti et al.
CLINICAL CANCER RESEARCH (2015)
Treatment effect of buparlisib, cetuximab and irradiation in wild-type or PI3KCA-mutated head and neck cancer cell lines
Laura Lattanzio et al.
INVESTIGATIONAL NEW DRUGS (2015)
Epidemiology of Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma
Maura L. Gillison et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Immunology and Immunotherapy of Head and Neck Cancer
Robert L. Ferris
JOURNAL OF CLINICAL ONCOLOGY (2015)
Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer
Juan Madoz-Gurpide et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2015)
Comprehensive genomic characterization of head and neck squamous cell carcinomas
Michael S. Lawrence et al.
NATURE (2015)
Increase in head and neck cancer in younger patients due to human papillomavirus (HPV)
David Young et al.
ORAL ONCOLOGY (2015)
Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma
Patcharee Ritprajak et al.
ORAL ONCOLOGY (2015)
Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients
Emanuela Romano et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
The future of immune checkpoint therapy
Padmanee Sharma et al.
SCIENCE (2015)
Head and neck cancer subtypes with biological and clinical relevance: Meta-analysis of gene-expression data
Loris De Cecco et al.
ONCOTARGET (2015)
Role of Local Radiation Therapy in Cancer Immunotherapy
Sandra Demaria et al.
JAMA ONCOLOGY (2015)
The tumour stromal features are associated with resistance to 5-FU-based chemoradiotherapy and a poor prognosis in patients with oral squamous cell carcinoma
Yuichiro Matsuoka et al.
APMIS (2015)
Integrative Analysis of Head and Neck Cancer Identifies Two Biologically Distinct HPV and Three Non-HPV Subtypes
Michaela K. Keck et al.
CLINICAL CANCER RESEARCH (2015)
Aurora Kinase Inhibition Overcomes Cetuximab Resistance in Squamous Cell Cancer of the Head and Neck
Alexander Hoellein et al.
Oncotarget (2015)
The hypoxic tumor microenvironment and drug resistance against EGFR inhibitors: preclinical study in cetuximab-sensitive head and neck squamous cell carcinoma cell lines
Carolien Boeckx et al.
BMC RESEARCH NOTES (2015)
The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models
V. D'Amato et al.
BRITISH JOURNAL OF CANCER (2014)
Phase 1 and Pharmacokinetic Study of Everolimus in Combination With Cetuximab and Carboplatin for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Nabil F. Saba et al.
CANCER (2014)
Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab
Christiane Meyer et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Overcoming cetuximab resistance in HNSCC: The role of AURKB and DUSP proteins
Carolien Boeckx et al.
CANCER LETTERS (2014)
AXL Mediates Resistance to Cetuximab Therapy
Toni M. Brand et al.
CANCER RESEARCH (2014)
Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC)
Roger B. Cohen
CANCER TREATMENT REVIEWS (2014)
Targeted therapies for squamous cell carcinoma of the head and neck: Current knowledge and future directions
Sandra Schmitz et al.
CANCER TREATMENT REVIEWS (2014)
RAS/PI3K Crosstalk and Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma
T. Rampias et al.
CLINICAL CANCER RESEARCH (2014)
Enhancement of head and neck squamous cell carcinoma proliferation, invasion, and metastasis by tumor-associated fibroblasts in preclinical models
Sarah Elizabeth Wheeler et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2014)
Tumor-Associated Macrophages: From Mechanisms to Therapy
Roy Noy et al.
IMMUNITY (2014)
mTOR Co-Targeting in Cetuximab Resistance in Head and Neck Cancers Harboring PIK3CA and RAS Mutations
Zhiyong Wang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
A role for p38 MAPK in head and neck cancer cell growth and tumor-induced angiogenesis and lymphangiogenesis
Kantima Leelahavanichkul et al.
MOLECULAR ONCOLOGY (2014)
The role of the PD-L1: PD-1 pathway in squamous cell carcinoma of the head and neck
Dan P. Zandberg et al.
ORAL ONCOLOGY (2014)
Characterization of HPV and host genome interactions in primary head and neck cancers
Michael a Parfenov et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Tumor Microenvironment in Head and Neck Squamous Cell Carcinoma
Joseph M. Curry et al.
SEMINARS IN ONCOLOGY (2014)
Bortezomib sensitises TRAIL-resistant HPV-positive head and neck cancer cells to TRAIL through a caspase-dependent, E6-independent mechanism
J. Bullenkamp et al.
CELL DEATH & DISEASE (2014)
The response of head and neck squamous cell carcinoma to cetuximab treatment depends on Aurora kinase A polymorphism
Anja Pickhard et al.
ONCOTARGET (2014)
Oncolytic immunotherapy: dying the right way is a key to eliciting potent antitumor immunity
Zong Sheng Guo et al.
FRONTIERS IN ONCOLOGY (2014)
Targeting PI3K/Akt/mTOR signaling in cancer
Camillo Porta et al.
FRONTIERS IN ONCOLOGY (2014)
Phase Ib/II study of the PI3Kα inhibitor BYL719 in combination with cetuximab in recurrent/metastatic squamous cell cancer of the head and neck (SCCHN)
Albiruni R. A. Razak et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck
A. Argiris et al.
ANNALS OF ONCOLOGY (2013)
Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients
H-B Jie et al.
BRITISH JOURNAL OF CANCER (2013)
TLR8 stimulation enhances cetuximab-mediated natural killer cell lysis of head and neck cancer cells and dendritic cell cross-priming of EGFR-specific CD8+ T cells
Ryan M. Stephenson et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Hedgehog Signaling Alters Reliance on EGF Receptor Signaling and Mediates Anti-EGFR Therapeutic Resistance in Head and Neck Cancer
Stephen B. Keysar et al.
CANCER RESEARCH (2013)
Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma
Sofia Lyford-Pike et al.
CANCER RESEARCH (2013)
Functional Characterization of Novel Mutations Affecting Survivin (BIRC5)-Mediated Therapy Resistance in Head and Neck Cancer Patients
Shirley K. Knauer et al.
HUMAN MUTATION (2013)
The immune system and head and neck squamous cell carcinoma: from carcinogenesis to new therapeutic opportunities
Monika E. Freiser et al.
IMMUNOLOGIC RESEARCH (2013)
Myeloid-derived suppressor cells in cancer: recent progress and prospects
Yazan S. Khaled et al.
IMMUNOLOGY AND CELL BIOLOGY (2013)
M2-polarized tumor-associated macrophages promoted epithelial-mesenchymal transition in pancreatic cancer cells, partially through TLR4/IL-10 signaling pathway
Chao-Ying Liu et al.
LABORATORY INVESTIGATION (2013)
Cetuximab Reverses the Warburg Effect by Inhibiting HIF-1-Regulated LDH-A
Haiquan Lu et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Michael S. Lawrence et al.
NATURE (2013)
Innate and adaptive immune cells in the tumor microenvironment
Thomas F. Gajewski et al.
NATURE IMMUNOLOGY (2013)
The quest to overcome resistance to EGFR-targeted therapies in cancer
Curtis R. Chong et al.
NATURE MEDICINE (2013)
Anti-Epidermal Growth Factor Receptor Therapy in Head and Neck Squamous Cell Carcinoma: Focus on Potential Molecular Mechanisms of Drug Resistance
Carolien Boeckx et al.
ONCOLOGIST (2013)
A randomized phase II study of docetaxel with or without vandetanib in recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN)
Sewanti Limaye et al.
ORAL ONCOLOGY (2013)
Tumor-associated macrophages and the profile of inflammatory cytokines in oral squamous cell carcinoma
Nadia Lago Costa et al.
ORAL ONCOLOGY (2013)
Epithelial to mesenchymal transition in head and neck squamous cell carcinoma
Ashley Smith et al.
ORAL ONCOLOGY (2013)
Molecular Subtypes in Head and Neck Cancer Exhibit Distinct Patterns of Chromosomal Gain and Loss of Canonical Cancer Genes
Vonn Walter et al.
PLOS ONE (2013)
Acquired resistance to cetuximab is associated with the overexpression of Ras family members and the loss of radiosensitization in head and neck cancer cells
Mohammad Saki et al.
RADIOTHERAPY AND ONCOLOGY (2013)
mTORC1 Inhibition Is Required for Sensitivity to PI3K p110α Inhibitors in PIK3CA-Mutant Breast Cancer
Moshe Elkabets et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
The Tumor Microenvironment Contribution to Development, Growth, Invasion and Metastasis of Head and Neck Squamous Cell Carcinomas
Sittichai Koontongkaew
JOURNAL OF CANCER (2013)
The anti-EGFR antibody cetuximab sensitizes human head and neck squamous cell carcinoma cells to radiation in part through inhibiting radiation-induced upregulation of HIF-1α
Haiquan Lu et al.
CANCER LETTERS (2012)
Targeting Stat3 Abrogates EGFR Inhibitor Resistance in Cancer
Malabika Sen et al.
CLINICAL CANCER RESEARCH (2012)
Decreased levels of alternative co-stimulatory receptors OX40 and 4-1BB characterise T cells from head and neck cancer patients
Paramita Baruah et al.
IMMUNOBIOLOGY (2012)
Hyaluronan-CD44v3 Interaction with Oct4-Sox2-Nanog Promotes miR-302 Expression Leading to Self-renewal, Clonal Formation, and Cisplatin Resistance in Cancer Stem Cells from Head and Neck Squamous Cell Carcinoma
Lilly Y. W. Bourguignon et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Role of Neurofilament Light Polypeptide in Head and Neck Cancer Chemoresistance
Baishen Chen et al.
MOLECULAR CANCER RESEARCH (2012)
Cancer-Associated Fibroblasts Induce Matrix Metalloproteinase-Mediated Cetuximab Resistance in Head and Neck Squamous Cell Carcinoma Cells
Ann-Charlotte Johansson et al.
MOLECULAR CANCER RESEARCH (2012)
YM155 Reverses Cisplatin Resistance in Head and Neck Cancer by Decreasing Cytoplasmic Survivin Levels
Bhavna Kumar et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Inhibition of TGF-β Enhances the In Vivo Antitumor Efficacy of EGF Receptor-Targeted Therapy
Atul Bedi et al.
MOLECULAR CANCER THERAPEUTICS (2012)
XIAP Is a Predictor of Cisplatin-Based Chemotherapy Response and Prognosis for Patients with Advanced Head and Neck Cancer
Xi-Hu Yang et al.
PLOS ONE (2012)
A CD44high/EGFRlow Subpopulation within Head and Neck Cancer Cell Lines Shows an Epithelial-Mesenchymal Transition Phenotype and Resistance to Treatment
Linnea La Fleur et al.
PLOS ONE (2012)
EMT Inducers Catalyze Malignant Transformation of Mammary Epithelial Cells and Drive Tumorigenesis towards Claudin-Low Tumors in Transgenic Mice
Anne-Pierre Morel et al.
PLOS GENETICS (2012)
Epidermal growth factor receptor (EGFR) expression and mutations in the EGFR signaling pathway in correlation with anti-EGFR therapy in head and neck squamous cell carcinomas
P. Smilek et al.
NEOPLASMA (2012)
Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia
Qing Zhou et al.
BLOOD (2011)
Deficiency of activated STAT1 in head and neck cancer cells mediates TAP1-dependent escape from cytotoxic T lymphocytes
Michael S. Leibowitz et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)
Inhibition of EGFR-STAT3 Signaling with Erlotinib Prevents Carcinogenesis in a Chemically-Induced Mouse Model of Oral Squamous Cell Carcinoma
Rebecca J. Leeman-Neill et al.
CANCER PREVENTION RESEARCH (2011)
p53 Modulates Acquired Resistance to EGFR Inhibitors and Radiation
Shyhmin Huang et al.
CANCER RESEARCH (2011)
Dual Kinase Inhibition of EGFR and HER2 Overcomes Resistance to Cetuximab in a Novel In Vivo Model of Acquired Cetuximab Resistance
Kelly M. Quesnelle et al.
CLINICAL CANCER RESEARCH (2011)
Expression of Amphiregulin and EGFRvIII Affect Outcome of Patients with Squamous Cell Carcinoma of the Head and Neck Receiving Cetuximab-Docetaxel Treatment
Ingeborg Tinhofer et al.
CLINICAL CANCER RESEARCH (2011)
INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR INHIBITOR, AMG-479, IN CETUXIMAB-REFRACTORY HEAD AND NECK SQUAMOUS CELL CARCINOMA
Christine H. Chung et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2011)
Natural killer (NK):dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity
Steve C. Lee et al.
IMMUNOLOGIC RESEARCH (2011)
Mechanisms underlying resistance to cetuximab in the HNSCC cell line: Role of AKT inhibition in bypassing this resistance
Magali Rebucci et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2011)
Immune parameters affecting the efficacy of chemotherapeutic regimens
Laurence Zitvogel et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
The mTOR-targeting drug temsirolimus enhances the growth-inhibiting effects of the cetuximab-bevacizumab-irradiation combination on head and neck cancer xenografts
Alexandre Bozec et al.
ORAL ONCOLOGY (2011)
Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers
Luc G. T. Morri et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Epithelial-mesenchymal-transition induced by EGFR activation interferes with cell migration and response to irradiation and cetuximab in head and neck cancer cells
Carmen Holz et al.
RADIOTHERAPY AND ONCOLOGY (2011)
Inhibition of STAT-3 results in greater cetuximab sensitivity in head and neck squamous cell carcinoma
James A. Bonner et al.
RADIOTHERAPY AND ONCOLOGY (2011)
Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
Kimio Yonesaka et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
MAPKs activation in head and neck squamous cell carcinomas
Daniele Maggioni et al.
ONCOLOGY REVIEWS (2011)
Development of cetuximab-resistant human nasopharyngeal carcinoma cell lines and mechanisms of drug resistance
Qiang Zuo et al.
BIOMEDICINE & PHARMACOTHERAPY (2010)
New Strategies in Head and Neck Cancer: Understanding Resistance to Epidermal Growth Factor Receptor Inhibitors
Lucy F. Chen et al.
CLINICAL CANCER RESEARCH (2010)
Understanding resistance to EGFR inhibitors-impact on future treatment strategies
Deric L. Wheeler et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
Evidence for mesenchymal-like sub-populations within squamous cell carcinomas possessing chemoresistance and phenotypic plasticity
D. Basu et al.
ONCOGENE (2010)
Regulation of Heparin-Binding EGF-Like Growth Factor by miR-212 and Acquired Cetuximab-Resistance in Head and Neck Squamous Cell Carcinoma
Hiromitsu Hatakeyama et al.
PLOS ONE (2010)
Dasatinib blocks cetuximab- and radiation-induced nuclear translocation of the epidermal growth factor receptor in head and neck squamous cell carcinoma
Chunrong Li et al.
RADIOTHERAPY AND ONCOLOGY (2010)
Triggering of Toll-like Receptor 4 Expressed on Human Head and Neck Squamous Cell Carcinoma Promotes Tumor Development and Protects the Tumor from Immune Attack
Miroslaw J. Szczepanski et al.
CANCER RESEARCH (2009)
Bcl-2 Blocks Cisplatin-Induced Apoptosis and Predicts Poor Outcome Following Chemoradiation Treatment in Advanced Oropharyngeal Squamous Cell Carcinoma
William A. Michaud et al.
CLINICAL CANCER RESEARCH (2009)
Wnt/β-Catenin Signaling: Components, Mechanisms, and Diseases
Bryan T. MacDonald et al.
DEVELOPMENTAL CELL (2009)
Nuclear EGFR contributes to acquired resistance to cetuximab
C. Li et al.
ONCOGENE (2009)
TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer
M. Szajnik et al.
ONCOGENE (2009)
Drug therapy: EGFR antagonists in cancer treatment
Fortunato Ciardiello et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Platinum-based chemotherapy plus cetuximab in head and neck cancer
Jan B. Vermorken et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members
D. L. Wheeler et al.
ONCOGENE (2008)
CTLA-4 control over Foxp3+ regulatory T cell function
Kajsa Wing et al.
SCIENCE (2008)
ATR-Chk2 signaling in p53 activation and DNA damage response during cisplatin-induced apoptosis
Navjotsingh Pabla et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Molecular targeted therapy of head and neck cancer: Review and clinical development challenges
Christophe Le Tourneau et al.
EUROPEAN JOURNAL OF CANCER (2007)
Drug resistance and the solid tumor microenvironment
Olivier Tredan et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor
Hideharu Kimura et al.
CANCER SCIENCE (2007)
Insulin-like growth factor receptor as a therapeutic target in head and neck cancer
Christopher J. Barnes et al.
CLINICAL CANCER RESEARCH (2007)
Phase II study of combination cetuximab and weekly paclitaxel in patients with metastatic/recurrent squamous cell carcinoma of head and neck (SCCHN): Spanish Head and Neck Cancer Group (TTCC)
R. Hitt et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
MAP kinase signalling pathways in cancer
A. S. Dhillon et al.
ONCOGENE (2007)
TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance
Weigang He et al.
MOLECULAR IMMUNOLOGY (2007)
Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy
Jan B. Vermorken et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
The role of VEGF and EGFR inhibition: Implications for combining anti-VEGF and anti-EGFR agents
Josep Tabernero
MOLECULAR CANCER RESEARCH (2007)
Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting
John C. Sok et al.
CLINICAL CANCER RESEARCH (2006)
Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer
Robert L. Ferris et al.
CLINICAL CANCER RESEARCH (2006)
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck
JA Bonner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
ERBB receptors and cancer: The complexity of targeted inhibitors
NE Hynes et al.
NATURE REVIEWS CANCER (2005)
Timeline - The discovery of receptor tyrosine kinases: targets for cancer therapy
A Gschwind et al.
NATURE REVIEWS CANCER (2004)
Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression
CH Chung et al.
CANCER CELL (2004)
Review of epidermal growth factor receptor biology
RS Herbst
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2004)
Src family kinases, key regulators of signal transduction
SJ Parsons et al.
ONCOGENE (2004)
A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage
TT Paull et al.
CURRENT BIOLOGY (2000)
分享论文
